Study Illuminates Link Between Hematuria Remission and Outcomes for Immunoglobulin A Nephropathy Patients
source: pixabay.com

Study Illuminates Link Between Hematuria Remission and Outcomes for Immunoglobulin A Nephropathy Patients

Immunoglobulin A nephropathy (IgAN) is a glomerular disease which can lead to kidney failure. Between 70 and 100 percent of all IgAN patients also are diagnosed with microscopic hematuria, but…

Continue Reading Study Illuminates Link Between Hematuria Remission and Outcomes for Immunoglobulin A Nephropathy Patients
Unmet Needs in the Treatment of Certain Glomerular Diseases
source: pixabay.com

Unmet Needs in the Treatment of Certain Glomerular Diseases

by Lauren Taylor from In The Cloud Copy Nephrologists worldwide have shown that there is a huge unmet need when it comes to the treatment of various glomerular diseases, in…

Continue Reading Unmet Needs in the Treatment of Certain Glomerular Diseases
All Patients Enrolled in Sparsentan Trial for FSGS
Photo by Robina Weermeijer on Unsplash

All Patients Enrolled in Sparsentan Trial for FSGS

On November 30, 2020, biopharmaceutical company Travere Therapeutics ("Travere") announced that patient enrollment was complete for the Phase 3 DUPLEX clinical trial. Within the trial, researchers will evaluate the safety,…

Continue Reading All Patients Enrolled in Sparsentan Trial for FSGS
Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings
source: pixabay.com

Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings

According to a story from GlobeNewswire, the biopharmaceutical company Reata Pharmaceuticals, Inc., recently announced that year two of its phase 3 clinical trial has been completed. This trial is testing…

Continue Reading Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings

Study: Glomerular Diseases Linked to Greater Risk of Cardivascular Disease

According to a story from Newswise, a recent study concluded that adult patients living with glomerular diseases face an increased chance of cardiovascular disease as well. The findings were first…

Continue Reading Study: Glomerular Diseases Linked to Greater Risk of Cardivascular Disease

Joint Efforts by Korean and California Research Teams Develop A Drug That Restores Renal Intervascular Cell Function

A recent article in the Korea Biomed Review reported that the joint research effort by Seoul National Medical College and Helixmith of San Diego, California, found Helixmith’s VM507 antibody effective…

Continue Reading Joint Efforts by Korean and California Research Teams Develop A Drug That Restores Renal Intervascular Cell Function
Acthar Gel Reduces Proteinuria for IgA Nephropathy Patients in Pilot Study
source: pixabay.com

Acthar Gel Reduces Proteinuria for IgA Nephropathy Patients in Pilot Study

According to a story from Yahoo Finance, the biopharmaceutical company Mallinckrodt recently released findings from an open label pilot study which tested the impact of Acthar Gel (corticotropin injection) as…

Continue Reading Acthar Gel Reduces Proteinuria for IgA Nephropathy Patients in Pilot Study

Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Apellis Pharmaceuticals has just announced that they have received Orphan Drug Designation from the FDA for APL-2, a C3 complement inhibitor. The company is currently investigating the drug as a…

Continue Reading Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Dosing Begins in Phase 3 IgA Nephropathy Clinical Trial

According to a story from BioSpace, the biopharmaceutical company Retrophin, Inc., recently announced that the first patient has been treated in the company's Phase 3 clinical trial testing sparsentan as…

Continue Reading Dosing Begins in Phase 3 IgA Nephropathy Clinical Trial
A Treatment for Thrombotic Microangiopathy Has Been Awarded Breakthrough Status by the F.D.A.
Source: Pixabay

A Treatment for Thrombotic Microangiopathy Has Been Awarded Breakthrough Status by the F.D.A.

The US Food and Drug Administration (FDA) has just awarded Breakthrough Therapy Designation to a drug (OMS721) being developed to treat thrombotic microangiopathy that has developed as a result of haematopoietic stem…

Continue Reading A Treatment for Thrombotic Microangiopathy Has Been Awarded Breakthrough Status by the F.D.A.